Pancreatic islet transplantation for treating diabetes

Expert Opinion on Biological Therapy

Volumn 6, Issue 1, 2006, Pages 23-37

  Matsumoto, Shinichi ^a   Noguchi, Hirofumi ^a   Yonekawa, Yukihide ^a   Okitsu, Teru ^a   Iwanaga, Yasuhiro ^a   Liu, Xiaoling ^a   Nagata, Hideo ^a,b   Kobayashi, Naoya ^c   Ricordi, Camillo ^d  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes Research Institute Federation; Islet transplantation; Kyoto Islet Isolation Method; Living donor islet; Non heart beating donor; Transplantation; Type 1 diabetes

Indexed keywords

15 DEOXYSPERGUALIN; ADENOSINE TRIPHOSPHATE; BELATACEPT; COLLAGENASE; CORTICOSTEROID; CYTOKINE; DEFEROXAMINE; ETANERCEPT; EVEROLIMUS; FINGOLIMOD; FLUOROCARBON; GLUCOSE; HEMOGLOBIN A1C; INFLIXIMAB; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LAZAROID; LIBERASE; LISOFYLLINE; NICOTINAMIDE; NORPHENAZONE; PRAVASTATIN; PREDNISONE; PRESERVATION SOLUTION; RAPAMYCIN; SILICON DIOXIDE; TACROLIMUS; ULINASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIVERSITY OF WISCONSIN SOLUTION;

CADAVER DONOR; DIABETES MELLITUS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPOGLYCEMIA; KIDNEY TRANSPLANTATION; LIVING DONOR; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; QUALITY OF LIFE; REVIEW;

ANIMALS; CLINICAL TRIALS; DIABETES MELLITUS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LIVING DONORS; MODELS, BIOLOGICAL;

EID: 30044451317     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.1.23     Document Type: Review

References (214)

1. BOYLE JP, HONEYCUTT AA, NARAYAN KM et al.: Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care (2001) 24:1936-1940.
2. DCCT RES GROUP: Diabetes control and complications trial (DCCT) Update. Diabetes Care (1990) 13:427-433.
3. DCCT RES GROUP: Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care (1995) 18:1415-1427.
4. VENSTROM JM, MCBRIDE MA, ROTHER KI, HIRSHBERG B, ORCHARD TJ, HARLAN DM: Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA (2003) 290:2817-2823. Current update of the risks of pancreas transplantation.
5. NAJARIAN JS, SUTHERLAND DE, MATAS AJ et al.: Human islet transplantation: A preliminary report. Transplant. Proc. (1977) 9:233-236.
6. HERING B, RICORDI C: Islet transplantation for patients with Type 1 diabetes: results, research priorities, and reasons for optimism. Graft (1999) 2:12-27.
7. RICORDI C, STROM TB: Clinical islet transplantation: advances and immunological challenges. Nat. Rev. Immuunol. (2004) 4:259-268. Current update of islet transplantation.
8. SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. (2000) 343:230-238. First reliable islet transplantation protocol for type 1 diabetes.
9. ROTHER KI, HARLAN DM: Challenges facing islet transplantation for the treatment of Type 1 diabetes mellitus. J. Clin. Invest. (2004) 114:877-883.
10. BAIDAL DA, FROUD T, FERREIRA JV, KHAN A, ALEJANDRO R, RICORDI C: The bag method for islet cell infusion. Cell Transplant. (2003) 12:809-813.
11. FROUD T, YRIZARRY JM, ALEJANDRO A, RICORDI C: Use of D-Stat™ to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. (2004) 13:55-59.
12. SHAPIRO AM, RICORDI C, HERING B: Edmonton's islet success has indeed been replicated in elsewhere. Lancet (2003) 362:1212.
13. AULT A: Edmonton's islet success tough to duplicate elsewhere. Lancet (2003) 361:2054.
14. SHAPIRO AM, LAKEY JR, PATY BW et al.: Strategic opportunities in clinical islet transplantation. Transplantation (2005) 79:1304-1307.
15. RYAN EA, PATY BW, SENIOR PA et al.: Five-year follow-up after clinical islet transplantation. Diabetes (2005) 54:2060-2069. Current update of the Edmonton protocol.
16. COUZIN J: Diabetes. Islet transplants face test of time. Science (2004) 306:34-37.
17. ROBERTSON RP: Islet transplantation: travels up the learning curve. Curr. Diab. Res. (2002) 2:365-370.
18. POGGIOLI R, PONTE G, BAIDAL DA et al.: Quality of life after islet transplantation. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-099.
19. BARSHES NR, VANATTA JC, BRUNICARDI F, UDELL IW, BALKRISHNAN R, GOSS JA: Health-related quality of life after pancreatic islet transplantation: a longitudinal study. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-145.
20. KAUFMAN DB, BAKER MS, CHEN X, LEVENTHAL JR, STUART FP: Sequential kidney/islet transplantation using prednisone-free immunosuppression. Am. J. Transplant. (2002) 2:674-677. Islet after kidney transplantation worked better than islet transplantation alone.
21. FROUD T, BAIDAL DA, CURE P et al.: Islet after kidney transplantation, Miami experience. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-047.
22. TOSO C, BAERTSCHIGER R, MOREL P et al.: Insulin independence in recipients of islet after kidney allogeneic transplantation using a steroid-free protocol. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-046.
23. DENG S, VELIDEDEOGLU E, FRANK A et al.: Comparison of the early outcome of islet alone transplants. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-043.
24. ANDRES A, TOSO C, MOREL P et al.: Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation. Transplant. Proc. (2005) 37:1326-1327.
25. MARKMANN JF, DENG S, DESAI NM et al.: The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation (2003) 75:1423-1429.
26. MATSUMOTO S, TANAKA K: Pancreatic islet cell transplantation using non-heart-beating-donors (NHBDs). J. Hepato-Biliary-Pancreatic Surg. (2005) 12:227-230.
27. MATSUMOTO S, TANAKA K, STRONG DM, REEMS JA: Efficacy of human islet isolation from the tail section of pancreas for the possibility of living donor islet transplantation. Transplantation (2004) 78:839-843. Tail section of the human pancreas is suitable for islet isolation, implicating living-donor islet transplantation.
28. MATSUMOTO S, OKITSU T, IWANAGA Y et al.: Successful islet transplantation from non-heart-beating donor pancreata using modified Ricordi islet isolation merhod. Transplantation (2006) (In Press). Substantial improvement of islet isolation method.
29. OKITSU T, MATSUMOTO S, IWANAGA Y et al.: Kyoto islet isolation method- The optimized one for non-heart-beating donors with highly efficient islet retrieval. Transplant. Proc. (2005) 37(8):3391-3392.
30. NAGATA H, MATSUMOTO S, IWANAGA Y et al.: Procurement of the human pancreas for pancreatic islet transplantation from marginal cadaver donors. Transplantation (2006) (In Press). Procurement method from NHBDs for islet isolation.
31. CORLETT MP, SHARP DW: The effect of pancreatic warm ischemia on islet isolation in rats and dogs. J. Surg. Res. (1988) 45:531-536.
32. SAWADA T, MATSUMOTO I, NAKANO M, KIRCHHOF N, SUTHERLAND DE, HERING BJ: Improved islet yield and function with ductal injection of University of Wisconsin solution before pancreas preservation. Transplantation (2003) 75:1965-1969. Concept of pancreatic ductal protection for improvement of islet isolation.
33. BANDO T, KOSAKA S, LIU C et al.: Effects of newly developed solutions containing trehalose on twenty-hour canine lung preservation. J. Thorac. Cardiovasc. Surg. (1994) 108:92-98.
34. LIU CJ, BANDO T, HIRAI T et al.: Improved 20-hour canine lung preservation with a new solution-ET-Kyoto solution. Eur. J. Cardiothorac. Surg. (1995) 9:548-552.
35. CONTRACTOR HH, JOHNSON PR, CHADWICK DR, ROBERTSON GS, LONDON NJ: The effect of UW solution and its components on the collagenase digestion of human and porcine pancreas. Cell Transplant. (1995) 4:615-619.
36. KAWAMURA T, KURODA Y, SUZUKI Y et al. Seventy-two-hour preservation of the canine pancreas by the two-layer (Euro-Collins' solution/perfluorochemical) cold storage method. Transplantation (1989) 47:776-778.
37. MATSUMOTO S, KURODA Y: Perfluorocarbon for organ preservation before transplantation. Transplantation (2002)74:1804-1809.
38. MATSUMOTO S: Clinical application of perfluorocarbons for organ preservation. Artif. Cells Blood Substit. Immobil. Biotechnol. (2005) 33:75-82. Update review of the two-layer method.
39. RIDGWAY DM, SWIFT SM, WHITE A et al.: Improvement of islet yield by pancreas preservation using trehalose containing solution. Acta Diabetol. (2003) 40:37.
40. BRANDHORST D, IKEN M, BRENDEL MD, BRETZEL RG, BRANDHORST H: Successful pancreas preservation by a perfluorocarbon-based one-layer method for subsequent pig islet isolation. Transplantation (2005) 79:443-437. Perfluorocarbon one-layer method for pancreas preservation.
41. MATSUMOTO S, RIGLEY T, QUALLEY S et al.: Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant. (2002) 11:769-777. Current standard pancreas preservation method prior to islet isolation.
42. MATSUMOTO S, RIGLEY T, REEMS J et al.: Improved islet yields from macaca nemestrina and marginal human pancreata after two-layer method preservation and endogenous trypsin inhibition. Am. J. Transplant. (2003) 3:53-63.
43. LAKEY JR, HELMS LM, KIN T et al.: Serine-protease inhibition during islet isolation increases islet yield from human pancreases with prolonged ischemia. Transplantation (2001) 72:565-570.
44. ROSE NL, PALCIC MM, HELMS LM, LAKEY JR: Evaluation of Pefabloc as a serine protease inhibitor during human-islet isolation. Transplantation (2003) 75:462-466.
45. ROSE NL, PALCIC MM, SHAPIRO AM, LAKEY JR: Endogenous pancreatic enzyme activity levels show no significant effect on human islet isolation yield. Cell Transplant. (2004) 13:153-160.
46. HEISER A, ULRICHS K, MULLER-RUCHHOLTZ W. Isolation of porcine pancreatic islets: low trypsin activity during the isolation procedure guarantees reproducible high islet yields. J. Clin. Lab. Anal. (1994) 8:407-411.
47. BASIR I, VAN DER BURG MP, SCHERINGA M, TONS A, BOUWMAN E: Improved outcome of pig islet isolation by Pefabloc inhibition of trypsin. Transplant. Proc. (1997) 29:1939-1941.
48. ROBERTSON GS, CHADWICK DR, DAVIES J et al.: The effectiveness of components of University of Wisconsin solution in improving human pancreatic islet purification. Transplantation (1994) 57:346-354.
49. VAN DER BURG MP, BASIR I, BOUWMAN E: No porcine islet loss during density gradient purification in a novel iodixanol in University of Wisconsin solution. Transplant. Proc. (1998) 30:362-363.
50. VAN DER BURG MP, GRAHAM JM: Iodixanol density gradient preparation in University of Wisconsin solution for porcine islet purification. Sci. World J. (2003) 3:1154-1159.
51. HERING BJ, KANDASWAMY R, HARMON JV et al.: Transplantation of cultured islets from two-layer preserved pancreases in Type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. (2004) 4:390-401.
52. HERING BJ, KANDASWAMY RR, ANSITE JD et al.: Single-donor, marginal-dose islet transplantation in patients with Type 1 diabetes. JAMA (2005) 293:830-835. Successful islet transplantation with a single donor.
53. HERING BJ: Achieving and maintaining insulin independent in human islet transplant recipients. Transplantation (2005) 79:1296-1297.
54. LAKEY JR, WARNOCK GL, RAJOTTE RV et al.: Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation (1996) 61:1047-1053.
55. MATSUMOTO S, YAMADA Y, OKITSU T et al.: Simple evaluation of engraftment by secretory unit of islet transplant object (SUITO) for living donor and cadaveric donor fresh or cultured islet transplantation. Transplant. Proc. (2005) 37(8):3435-3437.
56. FRANK A, DENG S, HUANG X et al.: Transplantation for Type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann. Surg. (2004) 240:631-640.
57. MATSUMOTO S, OKITSU T, IWANAGA Y et al.: Insulin independence after living donor distal pancreatectomy and islet allotransplantation. Lancet (2005) 365:1642-1644. First successful living-donor islet transplantation.
58. TAKADA M, NADEAU K, HANCOCK W et al.: Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation (1998) 65:1533-1542.
59. CONTRERAS JL, ECKSTEIN C, SMYTH CA et al.: Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes (2003) 52:2935-2942. Clear evidence of deterioration of islets during brain-dead status.
60. GRUESSNER RW, SUTHERLAND DE: Living donor pancreas transplantation. Transplant ACT. (2002) 16:108-119. Complete review of living-donor pancreas transplantation.
61. AMIEL SA, RELA M: Live organ-donation for islet transplantation. Lancet (2005) 365:1603-1604.
62. SLINGSBY BT, AKABAYASHI A: Live organ-donation for islet transplantation. Lancet (2005) 366:26-27.
63. RICORDI C, INVERARDI L, KENYON NS, GOSS J, BERTUZZI F, ALEJANDRO R: Requirements for success in clinical islet transplantation. Transplantation (2005) 79:1298-1300.
64. RICORDI C, LACY PE, LINKE EH, OLACK BJ, SHARP DW: Automated method for islet isolation of human pancreatic islets. Diabetes (1988) 37:413-420.
65. BENHAMOU, PY, WATT PC, MULLEN Y et al: Human islet isolation in 104 consecutive cases. Factors affecting isolation success. Transplantation (1994) 57:1804-1810.
66. BRANDHORST D, HERING BJ, BRANDHORST H, FEDERLIN K, BRETZEL RG: Influence of donor data and organ procurement on human islet isolation. Transplant. Proc. (1994) 26:592-593.
67. KETCHUM RJ, NICOLAE M, JAHR H et al.: Analysis of donor age and cold ischemic time as factors in cadaveric human islet isolation. Transplant. Proc. (1994) 26:596-597.
68. UNE S, ATIYA S, OHTUKA S et al.: Re-evaluation of donor factors affecting islet isolation from human pancreas using two-step digestion method. Transplant. Proc. (1997) 29:1969.
69. MATSUMOTO S, ZHANG G, QUALLEY S et al.: A. Analysis of donor factors affecting human islet isolation with current isolation protocol. Transplant. Proc. (2004) 36:1034-1036.
70. TSUJINO T, KOMATSU Y, ISAYAMA H et al.: Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled tirai. Clin. Gastroenterol. Hepatol. (2005) 3:376-383. Protective effect of ulinastatin for pancreatitis.
71. ALIVA JG, TSUJIMURA T, OBERHOLZER J et al.: Improvement of pancreatic islet isolation outcomes using glutamine perfusion during isolation procedure. Cell Transplant. (2003) 12:877-881.
72. AVILA JG, BARBARO B, ANTONIO G et al.: Intraductal glutamine administration reduces oxidative injury during human pancreatic islet isolation. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) PS-002.
73. CLARK LC, GOLLAN F: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science (1966) 152:1755-1756.
74. MATSUMOTO S, KANDASWAMY R, SUTHERLAND DE et al.: Clinical application of the two-layer [University of Wisconsin solution (UW)/perfluorochemical (PFC) plus O2] method of pancreas preservation before transplantation. Transplantation (2000) 70:771-774. The first clinical trial of the two-layer method.
75. MATSUMOTO S, KURODA Y, HAMANO M et al.: Direct evidence of pancreatic tissue oxygenation during preservation by the two-layer method. Transplantation (1996) 62:1667-1670.
76. TANIOKA Y, KURODA Y, KIM Y et al.: The effect of ouabain (inhibitor of an ATP-dependent Na+/K+ pump) on the pancreas graft during preservation by the two-layer method. Transplantation (1996) 62:1730-1734.
77. MATSUMOTO S, FUJINO Y, SUZUKI Y et al.: Evidence of protein synthesis during resuscitation of ischemically damaged canine pancreas by the two-layer method. Pancreas (2000) 20:411-414.
78. KURODA Y, FUJITA H, MATSUMOTO S et al.: Protection of canine pancreatic microvascular endothelium against cold ischemic injury during preservation by the two-layer method. Transplantation (1997) 64:948-953.
79. MATSUMOTO S, KURODA Y, SUZUKI Y, KU Y, FUJITA H, SAITOH Y: Thromboxane A2 synthesis inhibitor OKY046 ameliorates vascular endothelial injury of pancreas graft during preservation by the two-layer UW solution/perfluorochemical method at 20 degrees C. Transplant. Proc. (1997) 29:1359-1362.
80. PAPAS KK, HERING BJ, GUNTHER L, PAPPEL MJ, COLTON CK, AVGOUSTINIATOS ES: Pancreas oxygenation is inadequate during preservation with the two layer method. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-130.
81. LAKEY JR, WARNOCK GL, SHAPIRO AM et al.: Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant. (1999) 8:285-292.
82. LINETSKY E, BOTTINO R, LEHMANN R, ALEJANDRO R, INVERARDI L, RICORDI C: Improved human islet isolation using a new enzyme blend, Liberase. Diabetes (1997) 46:1120-1123. Improved islet isolation with current standard collagenase Liberase.
83. OLACK BJ, SWANSON CJ, HOWARD TK, MOHANAKUMAR T: Improved method for the isolation and purification of human islets of Langerhans using Liberase enzyme blend. Hum. Immunol. (1999) 60:1303-1309.
84. BARNETT MJ, ZHAI XW, LEGATT DF, CHENG SB, SHAPIRO AM, LAKEY JR: Quantitative assessment of collagenase blends for human islet isolation. Transplantation (2005) 80:723-728.
85. BUCHER P, MATHE Z, MOREL P et al.: Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation (2005) 79:91-97.
86. BRANDHORST H, BRANDHORST D, HESSE F et al.: Successful human islet isolation utilizing recombinant collagenase. Diabetes (2003) 52:91-97.
87. HERING BJ, MUENCH KP, SCHELZ J et al.: The evaluation of neutral density separation utilizing Ficoll-sodium diatrizoate and Nycodenz and centrifugal elutriation in the purification of bovine and canine islet preparations. Horm. Metab. Res. Suppl. (1990) 25:57-63.
88. LAKE SP, BASSETT PD, LARKINS A et al.: Large-sale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes (1989) 38(Suppl. 1):143-145.
89. MATSUMOTO S, ZHANG HJ, GILMORE T et al.: Large-scale isopycnic islet purification utilizing non-toxic, endotoixn-free media facilitates immediate single-donor pig islet allograft function. Transplantation (1998) 66(Suppl.):30.
90. MATSUMOTO S, SHIBATA S, KIRCHHOF N et al.: Immediate reversal of diabetes in primates following intraportal transplantation of porcine islets purified on a new histidine - lactobionate - iodixanol gradient. Transplantation (1999) 67:S220.
91. RYAN E, LAKEY J, RAJOTTE R et al.: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes (2001) 50:710-719.
92. RYAN E, LAKEY J, PATY B et al.: Successful islet transplantation: continued insulin reserve provide long-term glycemic control. Diabetes (2002) 51:2148-2157.
93. HERING BJ, WIJKSTROM M, ECKMAN PM: Islet transplantation. In: Transplantation of the Pancreas. Gruessner RWG, Sutherland DER (Eds), Springer-Verlag, New York, USA (2004):583-626. A thorough review of islet transplantation up until the Edmonton protocol.
94. KORSGREN O, NILSSON B, BERNE C et al.: Current status of clinical islet transplantation. Transplantation (2005) 79:1289-1293.
95. BENNET W, SUNDBERG B, GROTH C et al.: Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes (1999) 48:1907-1914.
96. MOBERG L, JOHANSSON H, LUKINIUS A et al.: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 360:2039-2045. A mechanism of poor engraftment of transplanted islets.
97. TITUS TT, HORTON PJ, BADET L et al.: Adverse outcome of human islet-allogenic blood interaction. Transplantation (2003) 75:1317-1322.
98. GOTO M, JOHANSSON H, MAEDA A, ELGUE G, KORSGREN O, NILSSON B: Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation (2004) 77:741-747. One of the most effective treatments to prevent IBMIR.
99. CONTRERAS JL, ECKSTEIN C, SMYTH CA: Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes (2004) 53:2804-2814. Another effective treatment to prevent IBMIR.
100. OZMEN L, EKDAHL KN, ELGUE G, LARSSON R, KORSGREN O, NILSSON B: Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets. Diabetes (2002) 51:1779-1784.
101. AKIMA S, HAWTHRONE WJ, FAVALORO EJ et al.: Tirofiban and activated protein C synergistically inhibit the instant blood mediated inflammatory reaction from islet cells exposure to blood. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-093.
102. FARNEY AC, XENOS E, SUTHERLAND DE et al.: Inhibition of pancreatic beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant. Proc. (1993) 25:865-866.
103. NASH JR, EVERSON NW, WOOD RF, BELL PR: Effect of silica and carrageenan on the survival of islet allografts. Transplantation (1980) 29:206-208.
104. NOMIKOS IN, PROWSE SJ, CAROTENUTO P, LAFFERTY KJ: Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes (1986) 35:1302-1304.
105. SHIBATA S, MATSUMOTO S, SAGESHIMA J et al.: Temporary treatment with sirolimus and low-trough cyclosporine prevents acute islet allograft rejection, and combination with starch-conjugated deferoxamin promotes islet engraftment in the preclinical pig model. Transplant. Proc. (2001) 33:509.
106. BRADLEY B, PROWSE SJ, BAULING P, LAFFERTY KJ: Desferrioxamine treatment prevents chronic islet allograft damage. Diabetes (1986) 35:550-555.
107. SANDBERG JO, EIZIRIK DL, SANDLER S, TRACEY DE, ANDERSSON A: Treatment with an iterleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes (1993) 42:1845-1851.
108. FAUST A, ROTHE H, SCHADE U, LAMPETER E, KOLB H: Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation (1996) 62:648-652.
109. RABINOVITCH A, SUAREZ WL, POWER RF: Lazaroid antioxidant reduces incidence of diabetes and insulitis in nonobese diabetic mice. J. Lab. Clin. Med. (1993) 121:603-607.
110. SHAPIRO AM, HAO E, RAJOTTE RV, KNETEMAN NM: Impact of Lazaroid U74006F on ischemia and reperfusion injury of islets after transplantation in rat. Transplant. Proc. (1996) 28:85-86.
111. ARITA S, SAUL J, JOH S et al.: Islet protective effect of pravastatin from nonspecific inflammation in mouse pancreatic islet isografts. Transplant. Proc. (1996) 28:924.
112. ARITA S, NAGAI T, OCHIAI M et al.: Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin. Transplantation (2002) 73:7-12.
113. BLEICH D, CHEN S, BURSTEN SL, NADLER JR: Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1 beta induced dysfunction in cultured rat islets. Endocrinology (1996) 137:4871-4877.
114. BOTTINO R, FERNANDEZ LA, RICORDI C et al.: Transplantation of allogeneic islets of Langerhans in the rat liver - effects of macrophage depletion on graft survival and microenvironment activation. Diabetes (1998) 47:316-323.
115. BROWN M, BRAUN M, MERCADO P, CICALESE L, BENEDETTI E, RASTELLINI C: Pyruvate improves pancreatic islet engraftment and functionality. Transplant. Proc. (2001) 33:3523.
116. BOTTINO R, BALAMURUGAN AN, BERTERA S, PIETROPAOLO M, TRUCCO M, PIGANELLI JD: Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. Diabetes (2002) 51:2561-2567.
117. RAO P, MAEDA H, SASAGURI S: Protective effect of a radical scavenger, MCI-186 on islet cell damages induced by oxidative stress. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-089.
118. UNGER RH, GRUNDY S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia (1985) 28:119-121.
119. SANDLER S, JANSSON L: Blood flow measurements in autotransplanted pancreatic islets of the rat. Impairment of the blood perfusion of the graft during hyperglycemia. J Clin. Invest. (1987) 80:17-21.
120. BRUNICARDI FC, STAGNER J, BONNER-WEIR S et al.: Microcirculation of the islets of Langerhans. Diabetes (1996) 45:385-392.
121. JANSSON L: The regulation of pancreatic islet blood flow. Diab. Metab. Rev. (1994) 10:407-416.
122. JANSSON L, CARLSSON P: Graft vascular function after transplantation of pancreatic islets. Diabetologia (2002) 45:749-763.
123. HAYEK A, LOPEZ AD, BEATTIE GM: Angiogenic peptides in pancreatic islet transplantation to diabetic rats. Transplantation (1990) 50:931-933.
124. STAGNER JI, SAMOLS E: Induction of angiogenesis by growth factors: relevance to pancreatic islet transplantation. EXS (1992) 61:381-385.
125. STAGNER JI, SAMOLS E: The induction of capillary bed development by endothelial growth factor before islet transplantation may prevent islet ischemia. Transplant. Proc. (1990) 22:824-828.
126. TRIVEDI N, STEIL GM, GOLTON CK, BONNER-WEIR S, WEIR GC: Improved vascularization of planar membrane diffusion devices following continuous infusion of vascular endothelial growth factor. Cell Transplant. (2000) 9:115-124.
127. LAI Y, SCHNEIDER D, KIDSZUN A et al.: Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine Pancreatic Islets. Transplantation (2005) 79:1530-1536.
128. JOHANSSON M, JANSSON L, CARLSSON P: Prolactin pretreatment improves islet transplantation outcome. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-104.
129. MATTSSOON G: The endothelial cells in islets of Langerhans. Ups. J. Med. Sci. (2005) 110:1-15.
130. ROSENBERG L, WANG R, PARASKEVAS S, MAYSINGER D: Structural and functional changes resulting from islet isolation lead to islet cell death. Surgery (1999) 126:393-398. Evidence that apoptosis of isolated islets occurs during the isolation process.
131. PARASKEVAS S, MAYSINGER D, WANG R, DUGUID TP, ROSENBERG L: Cell loss in isolated human islets occurs by apoptosis. Pancreas (2000) 20:270-276.
132. CATTAN P, BERNEY T, SCHENA S et al.: Early assessment of apoptosis in isolated islets of Langerhans. Transplantation (2001) 71:857-862.
133. THOMAS D, YANG H, BOFFA D et al.: Proapoptotic bax is hyperexpressed in isolated human islets compared with antiapoptotic bcl-2. Transplantation (2002) 74:1489-1496. Mechanisms of apoptosis of isolated human islets.
134. NAKANO M, YASUNAMI Y, MAKI T et al: Hepatocyte growth factor is essential for amelioration of hyperglycemia in streptozotocin-induced diabetic mice receiving a marginal mass of intrahepatic islet grafts. Transplantation (2000) 69:214-221.
135. GARCIA-OCANA A, TAKAE KK, SYED MA, PHILBRICK WM, VASAVADA RC, STEWART AF: Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J. Biol. Chem. (2000) 275:1226-1232.
136. GARCIA-OCANA A, VASAVADA RC, CEBRIAN A et al.: Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcome in mice. Diabetes (2001) 50:2752-2762.
137. GIANNOUKAKIS N, MI Z, RUDERT WA, GAMBOTTO A, TRUCCO M, ROBBINS P: Prevention of beta cell dysfunction and apoptosis activation in human islets by adnoviral gene transfer of the insulin-like growth factor I. Gene Ther. (2000) 7:2015-2022.
138. YE J, LAYCHOCK G: A protective role for heme oxygenase expression in pancreatic islets exposed to interleukin-1 beta. Endocrinology (1998) 139:4155-4163.
139. PILEGGI A, MOLANO RD, BERNEY T et al.: Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes (2001) 50:1983-1991.
140. TOBIASCH E, GUNTHER L, BACH FH: Heme oxygenase-1 protects pancreatic beta cells from apoptosis caused by various stimuli. J. Invest. Med. (2001) 49:566-571.
141. PILEGGI A, MOLANO RD, BERNEY T et al.: Prolonged allogeneic islet graft survival by protoporphyrins. Cell Transplant. (2005) 14:85-96.
142. FENJVES ES, OCHOA MS, GAY-RABINSTEIN C et al.: Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation (2004) 77:13-18.
143. RIACHY R, VANDEWALLE B, KERR CONTE J et al.: 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology (2002) 143:4809-4819.
144. ZHANG G, MATSUMOTO S, HYON SH, QUALLEY S, REEMS J: Polyphenol, an extract of green tea, increases culture recovery rates of islets isolated from non-human primate pancreata and marginal grade human pancreata. Cell Transplant. (2004) 13:145-152.
145. NAKANO M, MATSUMOTO I, SAWADA T et al.: Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas (2004) 29:104-109.
146. NOGUCHI H, NAKAI Y, MATSUMOTO S et al.: Cell permeable peptide JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function. Am. J. Transplant. (2005) 5:1848-1855.
147. HUI H, DOTTA F, DI MARIO U, PERFETTI R: Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J. Cell. Physiol. (2004) 200:177-200.
148. ROBERTSON P: Islet transplantation as a treatment for diabetes- A work in progress. N. Engl. J. Med. (2004) 350:694-705.
149. STREET CN, LAKEY JR, SHAPIRO AM et al.: Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome. Diabetes (2004) 53:3107-3114.
150. ISHIZUKA J, GUGLIUZZA KK, WASSMUTH Z et al.: Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation (1993) 56:1486-1490.
151. PATY BW, HARMON JS, MARSH CL, ROBERTSON RP: Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation (2002) 73:353-357.
152. FROUD T, PONTE G, PILEGGIA et al.: Use of mycophenolate mofetil in islet transplant: University of Miami experience. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-098.
153. FU F, HU S, DELEO J et al.: Long-term islet graft survival in streptozotosin and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation (2002) 73:1425-1430.
154. WJKSTROM M, KENYON NS, KIRCHHOF N et al.: Islet allograft survival in nonhuman primates immunosuppressed with basilisimab, RAD, and FTY 720. Transplantation (2004) 77:827-835.
155. ADAMS AB, SHIRASUGI N, DURHAM MM et al.: Calcineurin inhibitor-free CD28 blockage-based protocol protects allogeneic islets in nonhuman primates. Diabetes (2002) 51:265-270.
156. ADAMS AB, SHIRASUGI N, JONES TR et al.: Development of a chimeric anti-CD 40 monoclonal antibody that synergies with LEA29Y to prolong islet allograft survival. J. Immunol. (2005) 174:542-550.
157. HEROLAD KC, HAGOPIAN W, ECKHOFF DE et al.: Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med. (2002) 346:1692-1698.
158. KENYON NS, FERNANDEZ LA, LEHMANN R et al.: Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes (1999) 48:1473-1481.
159. LARSEN CP, PEARSON TC: The CD40 pathway in allograft rejection, acceptance and tolerance. Curr. Opin. Immunol. (1997) 9:641-647.
160. KLEIN D, BARBE-TUANA F, PUGLIESE A et al.: A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia (2005) 48:268-276.
161. BRINKMAN V, PINSCHEWER D, CHIBA K, FENG L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. (2000) 21:49-52.
162. DRAGUN D, BOHLER T, NIEMINEN-KELHA M et al.: FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. Kidney Int. (2004) 65:1076-1083.
163. ANSELMO DM, AMERSI FF, SHEN XD et al.: FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-cell infiltration. Am. J. Transplant. (2002) 2:843-849.
164. TRONSCOSO P, STEPKOWSKI SM, WANG ME et al.: Prophylaxis of acute renal allograft rejection using FTY720 in combination subtherapeutic doses of cyclosporine. Transplantation (1999) 67:145-151.
165. SCHUURMAN H, MENNINGER K, AUDET M et al.: Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or combination with cyclosporine or RAD. Transplantation (2002) 74:951-960.
166. FERGUSON R: FTY 720 immunomodulation: Optimism for improved transplantationregimens. Transplant. Proc. (2004) 36(Suppl.):549S-553S.
167. HELIO TS, GEORGES M, BARRY K et al.: FTY720, a novel immunomodulator: Efficacy and safety results from the first Phase IIA study in de novo renal transplantation. Transplantation (2005) 79:1553-1560.
168. LINDGREN M, HALLBRINK M, PROCHIANTZ A, LANGEL U: Cell-penetrating peptides. Trends Pharmacol. Sci. (2000) 21:99-103.
169. SCHWARZE SR, DOWDY SF: In vivo protein transduction: intracellular biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. (2000) 21:45-48.
170. NOGUCHI H, MASTUSHITA M, OKITSU T et al.: A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat. Med. (2004)
171. CONTRERAS JL, ECKHOFF DE, CARTNER S et al.: Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients. Transplantation (1999) 68:215-219.
172. KENYON NS, CHATZIPETROU M, MASETTI M et al.: Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD 154. Proc. Natl. Acad. Sci. USA (1999) 96:8132-8137. Large animal tolerance model of islet transplantation.
173. THOMAS JM, CONTRERAS JL, SMYTH CA et al.: Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of Type 1 diabetes. Diabetes (2001) 50:1227-1236. Large animal tolerance model of islet transplantation.
174. THOMAS JM, HUBBARD WJ, SOOUDI SK, THOMAS FT: STEALTH matters: a novel paradigm of durable primate allograft tolerance. Immunol. Rev. (2001) 183:223-233.
175. FONTES P, PAO AS, DEMETRIS AJ et al.: Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 344:151-155.
176. RASTELLINI C, SHAPIRO R, CORRY R, FUNG JJ, STARZL TE, RAO AS: An attempt to reserve diabetes by delayed islet cell transplantation in humans. Transplant. Proc. (1997) 29:2238-2239.
177. FARNEY AC, NAJARIAN JS, NAKHLEH RE et al.: Autotransplantation of dispersed pancreatic islet tissue combined with total or near-total pancreatectomy for treatment of chronic pancreatitis. Surgery (1991) 119:427-437. Clinical evidence of the effectiveness of islet autotransplantation for chronic pancreatitis.
178. ROBERTSON RP, LANZ KJ, SUTHERLAND DE et al.: Relationship between diabetes and obesity 9 to 18 years after hemipancreatectomy and transplantation in donors and recipients. Transplantation (2002) 73:736-741.
179. DOR Y, BROWN J, MARTINEZ OI, MELTON DA: Adult pancreatic beta-cell are formed by self-duplication rather than stem-cell differentiation. Nature (2004) 429:41-46.
180. THORENS B, PORRET A, BUHLER L, DENG SP, MOREL P, WIDMANN C: Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes (1993) 42:1678-1682.
181. ZHOU J, WANG X, PINEYRO MA, EGAN JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes (1999) 48:2358-2366.
182. STOFFERS DA, KIEFFER TJ, HUSSAIN MA et al.: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein PDX-1 and increase islet size in mouse pancreas. Diabetes (2000) 49:741-748.
183. GEDULIN BR, NIKOULINA SE, SMITH PA et al.: Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology (2005) 146:2069-2076.
184. LI L, EL-KHOLY W, RHODES C, BRUBAKER PL: Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia (2005) 48:1339-1349.
185. OTONKOSKI T, CIRULLI V, BEATTIE M et al.: A role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced pancreatic beta-cell growth. Endocrinology (1996) 271:1200-1208.
186. RAFAELOFF R, PITTENGER GL, BARLOW SW et al.: Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. J. Clin. Invest. (1997) 99:2100-2109.
187. TAM J, ROSENBERG L, MAYSINGER D: INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice. FASEB J. (2004) 18:1767-1769.
188. BENNET W, BJORKLAND A, SUNDBERG B et al.: A comparison of fetal and adult porcine islets with regard to Gal alpha (1,3)Gal expression and the role of human immunoglobulins and complement in islet cell cytotoxicity. Transplantation (2000) 69:1711-1717.
189. RAYAT GR, RAJOTTE RV, HERING BJ, BINETTE TM, KORBUTT GS: In vitro and in vivo expression of Galalpha-(1,3)Gal on porcine islet cells is age dependent. J. Endocrinol. (2003) 177:127-135.
190. WIJKSTROM M, KIRCHHOF N, PILON KJ et al.: Xenogeneic pig islets escape rejection in immunosuppressed primates but fail to sustain normoglycemia. Am. J. Transplant. (2001) 1:153.
191. WHITE DJG, VALDES R, DORANTES L et al.: Co-transplantation of porcine islets with Sertoli cells in Type 1 diabetic patients produces atypical humoral immune responses as assessed by elicited anti-pig antibodies. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) PS-100.
192. ELLIOTT RB, ESCOBAR L, TAN PL, VASCONCELLOS AV, EMERICH DF, THANOS C: Long term survival of alginate encapsulated piglet islets in a patient with Type l diabetes. Abstract Book of 10th World Congress of International Pancreas and Islet Transplant Association. Geneva, Switzerland (2005) OP-054.
193. YONEKAWA Y, MATSUMOTO S, OKITSU T et al.: Effective islet isolation method with extremely high islet yields from adult pigs. Cell Transplant. (2006) (In Press).
194. HENEINE W, TIBELL A, SWITZER WM et al.: No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet (1998) 352:695-699.
195. VAN DER LAAN LJ, LOCKEY C, GRIFFETH BC et al.: Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature (2000) 407:90-94. Caution about porcine endogenous retrovirus infection after islet xenotransplantation.
196. SWITZER WM, MICHLER RE, SHANMUGAM V et al.: Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs. Transplantation (2001) 71:959-965.
197. CLEMENCEAU B, JEGOU D, MARTIGNAT L, SAI P: Long-term follow-up failed to detect in vitro transmission of full-length porcine endogenous retroviruses from specific pathogen-free pig islets to human cells. Diabetologia (2001) 44:2044-2055.
198. GOTO M, MAEDA A, ELFMAN L et al.: No transmission of porcine endogenous retrovirus after transplantation of adult porcine islets into diabetic nude mice and immunosuppressed rats. Xenotransplantation (2004) 11:340-346.
199. SORIA B: In-vitro differentiation of pancreatic beta-cells. Differentiation (2001) 68:205-219.
200. SORIA B, SKOUDY A, MARTIN F: From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus. Diabetologia (2001) 44:407-415.
201. RAJAGOPAL J, ANDERSON WJ, KUME S, MARTINEZ OI, MELTON DA: Insulin staining of ES cell progeny from insulin uptake. Science (2003) 299:363. Insulin staining of ES cell progeny was due to uptake of insulin from culture medium.
202. HANSSON M, TONNING A, FRANDSEN U et al.: Artifactual insulin release from differentiated embryonic stem cells. Diabetes (2004) 53:2603-2609.
203. BONNER-WEIR S, TANEJA M, WEIR GC et al.: In vitro cultivation of human islets from expanded ductal tissue. Proc. Natl. Acad Sci. USA (2000) 97:7999-8004. Method for differentiation to islet-like cluster cells from non-endocrine tissue.
204. BONNER-WEIR S, TOSCHI E, INADA A et al.: The pancreatic ductal epithelium serves as a potential pool of progenitor cells. Pediatr. Diabetes (2004) 5(Suppl. 2):16-22.
205. JONSSON J, CARLSSON L, EDLUND T, EDLUND H: Insulin-promoter-factor 1 is required for pancreas development in mice. Nature (1994) 371:606-609.
206. OFFIELD MF, JETTON TL, LABOSKY PA et al.: PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development (1996) 122:983-995.
207. FERBER S, HALKIN A, COHEN H et al.: Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat. Med. (2000) 6:568-572.
208. NOGUCHI H, KANETO H, WEIR GC, BONNER-WEIRS: PDX-1 protein containing its own antennapedia-like protein transduction domain can transduce pancreatic duct and islet cells. Diabetes (2003) 52:1732-1737. PDX-1 could permeate cells and induce insulin gene expression in progenitor cells.
209. NOGUCHI H, MATSUSHITA M, MATSUMOTO S, LU YF, MATSUI H, BONNER-WEIR S: Mechanism of PDX-1 protein transduction. Biochem. Biophys. Res. Commun. (2005) 332:68-74.
210. SMITH SB, WATADA H, GERMAN MS: Neurogenin 3 activates the islet differentiation program while repressing its own expression. Mol. Endocrinol. (2004) 18:142-149.
211. NOGUCHI H, BONNER-WEIR S, WEI FY, MATSUSHITA M, MATSUMOTO S: BETA2/NeuroD protein can be transduced into cells due to an arginine- and lysine-rich sequence. Diabetes (2005) 54:2859-2866.
212. SOSA-PINEDA B: The gene Pax4 is an essential regulator of pancreatic beta-cell development. Mol. Cells (2004) 18:289-294.
213. HENSELEIT KD, NELSON SB, KUHLBRODT K, HENNINGS JC, ERICSON J, SANDER M: NKX6 transcription factor activity is required of alpha and beta cell development in the pancreas. Development (2005) 132:3139-3149.
214. DOMINGUEZ-BENDALA J, KLEIN D, RIBEIRO M et al.: TAT-mediated neurogenin 3 protein transduction stimulates pancreatic endocrine differentiation in vitro. Diabetes (2005) 54:720-726.